TNF-alpha Production by Peripheral Blood Monocytes in Multiple Sclerosis Patients and Healthy Controls

Immunological Investigations

Volumn 44, Issue 6, 2015, Pages 590-601

  Farrokhi, Mehrdad ^a,b   Etemadifar, Masoud ^a,b   Jafary Alavi, Maryam Sadat ^c   Zarkesh Esfahani, Sayyed Hamid ^c   Behjati, Mohaddeseh ^d   Rezaei, Ali ^e   Amani Beni, Ali ^a,b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Multiple Sclerosis and Neuroimmunology Research Center   (Iran)

^c UNIVERSITY OF ISFAHAN   (Iran)

^d ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e BROWN UNIVERSITY   (United States)

Author keywords

Flow cytometry; leptin; multiple sclerosis; tumor necrosis factor alpha

Indexed keywords

ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; IL6 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GOLGI COMPLEX; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LEUKOCYTE ACTIVATION; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; SAMPLE; BLOOD; IMMUNOLOGY; YOUNG ADULT;

ADULT; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MONOCYTES; MULTIPLE SCLEROSIS; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84939215468     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2015.1059851     Document Type: Article

References (32)

1. Batocchi AP, Rotondi M, Caggiula G, et al. (2003). Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. J Neuroimmunol, 139, 150-4
2. Begum F, Zhu W, Cortes C, et al. (2013). Elevation of tumor necrosis factor alpha in dorsal root ganglia and spinal cord is associated with neuroimmune modulation of pain in an animal model of multiple sclerosis. J Neuroimmune Pharmacol, 8, 677-90
3. Carrieri PB, Provitera V, Rosa TD, et al. (1998). Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis. A correlation with clinical activity. Immunopharmacol Immunotoxicol, 20, 373-82
4. Codarri L, Fontana A, Becher B, et al. (2010). Cytokine networks in multiple sclerosis: Lost in translation. Curr Opin Neurol, 23, 205-11
5. Faustman D, Davis M. (2010). TNF receptor 2 pathway: Drug target for autoimmune diseases. Nat Rev Drug Discov, 9, 482-93
6. Hasheminia SJ, Zarkesh-Esfahani SH, Toluei S, et al. (2014). Toll like receptor 2 and 4 expression in peripheral blood mononuclear cells of multiple sclerosis patients. Iran J Immunol, 11, 74-83
7. Hohnoki K, Inoue A, Koh CS, et al. (1998). Elevated serum levels of IFN-γ, IL-4 and TNF-α/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J Neuroimmunol, 87, 27-32
8. Holmoy T. (2007). Immunopathogenesis of multiple sclerosis: Concepts and controversies. Acta Neurol Scand, 87, 39-45
9. Imamura K, Suzumura A, Hayashi F, et al. (1993). Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurologica Scandinavica, 87, 281-5
10. Imitola J, Chitnis T, Khoury SJ, et al. (2005). Cytokines in multiple sclerosis: From bench to bedside. Pharmacol Therapeut, 106, 163-77
11. Kallaur AP, Oliveira SR, Delicato de Almeida ER, et al. (2013). Cytokine profile in relapsing-remitting multiple sclerosis patients and the association between progression and activity of the disease. Mol Med Rep, 7, 1010-20
12. Katsavos S, Anagnostouli M. (2013). Biomarkers in multiple sclerosis: An up-to-date overview. Multiple Sclerosis International, 2013, 1-20. ID 340508
13. Kouwenhoven M, Teleshova N, Özenci V, et al. (2001). Monocytes in multiple sclerosis: Phenotype and cytokine profile. J Neuroimmunol, 112, 197-205
14. Lam QL, Lu L. (2007). Role of leptin in immunity. Cell Mol Immuno, l4, 1-13
15. Leung JC, Chan LY, Lam MF, et al. (2012). The role of leptin and its short-form receptor in inflammation in db/db mice infused with peritoneal dialysis fluid. Nephrol Dialysis Transplant, 27, 3119-29
16. Lindquist S, Hassinger S, Lindquist JA, et al. (2011). The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: Effects of acute relapse and immunomodulatory treatment. Mult Scler J, 17, 851-66
17. Martins TB, Rose JW, Jaskowski TD, et al. (2011). Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am J Clin Pathol, 136, 696-704
18. Mellergård J, Edström M, Vrethem M, et al. (2010). Natalizumab treatment in multiple sclerosis: Marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler, 16, 208-17
19. Musabak U, Demirkaya S, Genç G, et al. (2010). Serum adiponectin, TNF-α, IL-12p70, and IL-13 levels in multiple sclerosis and the effects of different therapy regimens. Neuroimmunomodulation, 18, 57-66
20. Özenci V, Kouwenhoven M, Link H, et al. (2002). Cytokines in multiple sclerosis: Methodological aspects and pathogenic implications. Mult Scler, 8, 396-404
21. Patanella AK, Zinno M, Quaranta D, et al. (2010). Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients. J Neurosci Res, 88, 1106-12
22. Petrescu F, Voican SC, Silosi I, et al. (2010). Tumor necrosis factor-α serum levels in healthy smokers and nonsmokers. Int J Chronic Obstruct Pulmonary Dis, 5, 217-22
23. Re F, Strominger JL. (2001). Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem, 276, 37692-9
24. Reale M, de Angelis F, di Nicola M, et al. (2012). Relation between pro-inflammatory cytokines and acetylcholine levels in relapsing-remitting multiple sclerosis patients. Int J Mol Sci, 13, 12656-64
25. Roses RE, Xu S, Xu M, et al. (2008). Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J Immunol, 181, 5120-7
26. Srivastava P, Mujtaba MA, Singhal M, et al. (2012). Gene and cytokines expression of multiple sclerosis and its therapeutic regimen: A systemic review. Int J Drug Dev Res, 4, 55-66
27. Stepien A, Chalimoniuk M, Lubina-Dąbrowska N, et al. (2013). Effects of Interferon β-1a and Interferon β-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing-remitting multiple sclerosis: A 3-year longitudinal study. Neuroimmunomodulation, 20, 213-22
28. van der Bruggen T, Nijenhuis S, van Raaij E, et al. (1999). Lipopolysaccharide-induced tumor necrosis factor alpha production by human monocytes involves the raf-1/MEK1-MEK2/ERK1-ERK2 pathway. Infect Immunity, 67, 3824-9
29. Vladic A, Horvat G, Vukadin S, et al. (2002). Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. Cytokine, 20, 86-9
30. Yadav, AR, Deo N. (2013). Influence of leptin on immunity. Curr Immunol Rev, 9, 23-30
31. Zarkesh-Esfahani, H, Pockley G, Metcalfe RA, et al. (2001). High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol, 167, 4593-9
32. Zielinski, CC, Budinsky AC, Wagner TMU, et al. (2003). Defect of tumour necrosis factor-α (TNF-α) production and TNF-α-induced ICAM-1-expression in BRCA1 mutations carriers. Breast Cancer Res Treat, 81, 99-105